Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...

TD2 Oncology delivers fully integrated preclinical, regulatory, and clinical services for cancer drug development. In response to advances in In Vivo CAR-T engineering, TD2 Oncology launches flow ...

The discovery of novel immunotherapies that specifically target and enhance the T-cell response against cancer, for example CAR-T cells, bispecific antibodies and checkpoint inhibitors, is a rapidly ...

Flow-based methods allow researchers to collect multiparameter data from individual cells in their samples, but the fate of samples depends on the instrument. In addition to cell analysis, cell ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...